Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 8/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.39 |
| ▸ | NPY1R | P25929 | 6/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | TFPI | P10646 | 1/20 | 0.36 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.35 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15268407 | 0.94 | RXFP1 (0.42) | NOD1RXFP1NPY4RNPY5RNPY1R | |
| SCHEMBL15268406 | 0.94 | RXFP1 (0.42) | NOD1RXFP1NPY4RNPY5RNPY1R | |
| SCHEMBL607984 | 0.94 | NOD1 (0.40) | NOD1RXFP1NPY4RNPY5RNPY1R | |
| SCHEMBL607985 | 0.94 | NOD1 (0.40) | NOD1RXFP1NPY4RNPY5RNPY1R | |
| SCHEMBL6038374 | 0.92 | NPY4R (0.40) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30855541 | 0.92 | NPY4R (0.40) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6038377 | 0.92 | NPY4R (0.40) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29678580 | 0.90 | TERT (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29587324 | 0.89 | ENPEP (0.42) | NOD1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL10336105 | 0.89 | RXFP1 (0.52) | RXFP1NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309058-A1 | TUMOR HOMING AND CELL PENETRATING PEPTIDE-IMMUNO-ONCOLOGY AGENT COMPLEXES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2024-09-19 | — | — | US | disclosed |
| US-20240287147-A1 | PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2024-08-29 | — | — | US | disclosed |
| US-11866466-B2 | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | Blaze Bioscience, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309058-A1 | TUMOR HOMING AND CELL PENETRATING PEPTIDE-IMMUNO-ONCOLOGY AGENT COMPLEXES AND METHODS OF USE THEREOF | TAP1, CXCL12, CCL2 | NOD1 3817/4885RXFP1 686/4885NPY4R 878/4885 |
| US-20240287147-A1 | PD-L1 BINDING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | NOD1 893/4885RXFP1 1034/4885NPY4R 2355/4885 |
| US-11866466-B2 | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | TAP1, CXCL12, CCL2 | NOD1 3817/4885RXFP1 686/4885NPY4R 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.